IMMUNOREL (HUMAN NORMAL IMMUNOGLOBULIN) 10% 10G 100ML VIAL

Immunorel contains a concentrated solution of human IgG antibodies derived from pooled plasma of thousands of healthy donors. The large donor pool provides a broad spectrum of antibodies against a wide range of pathogens and antigens. It is used for two distinct purposes: immunoglobulin replacement therapy, and immunomodulation.

Replacement therapy (primary and secondary immunodeficiency):

•       Primary immunodeficiency disorders (PID): agammaglobulinaemia, common variable immunodeficiency (CVID), combined immunodeficiencies — replacing absent or severely depleted IgG antibodies

•       Secondary immunodeficiency: CLL, myeloma, bone marrow transplant — when disease or treatment has depleted immunoglobulin levels causing recurrent infection

Immunomodulation:

•       Immune thrombocytopenic purpura (ITP) — to rapidly raise platelet count

•       Kawasaki disease — reduces risk of coronary artery aneurysm if given within 10 days

•       Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP)

•       Multifocal motor neuropathy (MMN)

•       Other immune-mediated neurological and inflammatory conditions per specialist guidance

Dose by indication:

•       Replacement therapy (PID/SID): 0.4–0.8 g/kg every 3–4 weeks, titrated to trough IgG levels and clinical response

•       ITP: 0.8–1 g/kg/day for 1–2 days

•       Kawasaki disease: 2 g/kg as a single infusion (plus aspirin)

•       CIDP induction: 2 g/kg over 2–5 days; maintenance 1 g/kg every 3 weeks

Administration:

Infuse intravenously via a dedicated IV line — do not mix with other medicines or IV fluids. Start infusion slowly (0.5–1 mL/kg/hour) and increase rate gradually over 30 minutes if tolerated, per prescribing guidance. Each infusion typically takes 2–6 hours.

•       Vital signs must be monitored at 15–30-minute intervals throughout the first infusion and whenever the rate is increased

•       Pre-medication with paracetamol and antihistamine may be considered in patients with prior infusion reactions

•       Known selective IgA deficiency with anti-IgA antibodies — high risk of severe anaphylaxis. Screen all patients for IgA deficiency before the first infusion.

•       Known hypersensitivity to any human immunoglobulin preparation

•       Pre-existing renal impairment: ensure adequate renal function before use; monitor urea and creatinine during therapy — use at minimum effective concentration and infusion rate

•       Thrombotic risk factors (immobility, hypercoagulable states, advanced age, obesity, cardiovascular disease): high-dose IVIG increases thrombotic risk. Adequate hydration before, during, and after infusion is essential. Administer at the minimum effective infusion rate.

•       Live attenuated vaccines (MMR, varicella, yellow fever): IVIG can impair the immune response to live vaccines for up to 3 months after administration. Defer live vaccination by at least 3 months post-infusion.

•       Laboratory coagulation tests: IVIG may transiently affect coagulation test results — time blood tests appropriately

•       Nephrotoxic drugs (aminoglycosides, NSAIDs): caution if used concurrently — additive renal stress

Q: What is Immunorel used for?

It provides concentrated IgG antibodies either to replace missing antibodies in immune deficiency disorders (enabling the body to fight infections), or to modulate an overactive immune system in conditions like ITP, Kawasaki disease, and inflammatory nerve disorders.

Q: Is it made from human blood? - Is this safe?

Yes, it is made from pooled human plasma from thousands of donors. Manufacturing processes include multiple viral inactivation and removal steps that substantially reduce any infectious risk. The remaining theoretical risk of virus transmission is very small, but cannot be completely excluded. Your clinician will have assessed that the benefit of treatment outweighs this risk.

Q: I cannot have live vaccines after IVIG — what does this mean practically?

IVIG contains antibodies that can neutralise the weakened viruses in live vaccines (such as MMR, chickenpox, and yellow fever), making them less effective. These vaccines should be deferred for at least 3 months after an IVIG infusion. Your specialist or GP will advise on timing.

Q: How often do I need IVIG infusions?

For ongoing immunodeficiency replacement therapy, typically every 3–4 weeks — this is a lifelong treatment for most patients with PID. For conditions like ITP or Kawasaki disease, IVIG may be given as a short course. CIDP maintenance is typically every 3 weeks. Your specialist will determine the schedule based on your condition and response.